The grant will enable Melior to test the usage of a drug currently used in other disease areas for its effects in preclinical models of Parkinson’s disease.
MJFF Research Programs associate director Kuldip Dave said the development of new drugs is expensive and time-consuming and patients are left hanging in the balance.
"In fall 2010, MJFF launched our inaugural repositioning RFA to address these realities, and to attempt to reduce the time and costs involved in finding drugs that could help people living with Parkinson’s," Dave said.